Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation

This publication has 39 references indexed in Scilit:

• Breast MR Imaging in the Diagnostic Setting
  Magnetic Resonance Imaging Clinics of North America, 2006
• Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy
  Annals of Surgery, 2006
• Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue
  Gynecological Endocrinology, 2005
• Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies
  Clinical Cancer Research, 2004
• Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38− cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells
  Leukemia, 2004
• PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells
  Regulatory Peptides, 2002
• Comparison of an 18F Labeled Derivative of Vasoactive Intestinal Peptide and 2-Deoxy-2-[18F]Fluoro-D-Glucose in Nude Mice Bearing Breast Cancer Xenografts
  Molecular Imaging & Biology, 2002
• Murine mucosal T cells have VIP receptors functionally distinct from those on intestinal epithelial cells
  Journal of Neuroimmunology, 1992
• Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells
  Biochemical and Biophysical Research Communications, 1989
• Polypeptide with Broad Biological Activity: Isolation from Small Intestine
  Science, 1970